Amorfix appoints Dr Elliot Goldstein and Mr Warren Whitehead to Board of Directors

TORONTO, Sept. 4, 2014 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Dr. Elliot Goldstein and Mr. Warren Whitehead to its Board of Directors.

Dr. Goldstein is a veteran of the Pharmaceutical Industry with an impressive career that spans more than 30 years.  Dr. Goldstein began his career in 1980 at Sandoz Pharmaceuticals (now Novartis) where he was responsible for clinical development of numerous programs and eventually became Vice President of Clinical Research and Development at the Sandoz Research Institute managing a 200 person department. Dr. Goldstein then moved on to SmithKline Beecham Pharmaceuticals (now GSK) where he was SVP of worldwide strategic product development.  Dr. Goldstein was the Chief Executive Officer and an Executive Member of the Board of Directors of British Biotech from 1998 to 2002.  Following  that Dr. Goldstein was Chief Operating Officer/Chief Medical Officer at Maxigen, Inc. where he was responsible for the successful execution of all key operating functions, including process development, pharmacology/biology, molecular biology, clinical/regulatory, project management and quality assurance. He is a co-founder of Vitrua, LLC; a virtual development partner consulting firm, and is currently Chief Medical Officer of Immune Pharmaceuticals, a NASDAQ listed biotech company with a focus on personalized medicine in autoimmune disease and cancer.

Dr. Goldstein received his B.Sc. from McGill University and his MD from University Aix-Marseille II, Marseille, France

Mr. Whitehead, CPA, CMA, has been in the pharmaceutical industry for more than 25 years and has previously held top management positions in a number of leading private and publicly owned pharmaceutical companies.  Prior to joining Amorfix, Mr. Whitehead was CFO at Arius Research Inc., where he provided financial guidance and leadership during the acquisition of ARIUS by Roche in 2008 and prior to that he was CFO at Labopharm, Inc. where he completed a series of public equity financings and a NASDAQ IPO. Earlier, he held financial and business development positions at Glaxo Wellcome, (now GSK). He is currently a member of the Board of Directors of Lorus Therapeutics, (now Aptose Biosciences), and Chairman of PlantForm Corporation, plant based biosimilars. Mr. Whitehead received his MBA and BComm from the University of Windsor and his BA from The University of Western Ontario.

"We are extremely pleased to welcome Dr. Goldstein and Mr. Whitehead to the Amorfix Board of Directors", said Mr. William Wyman, Amorfix Chairman of the Board.  "Dr. Goldstein brings a wealth of Pharmaceutical Industry experience with a particular focus on clinical development as well as management of operations where he has made major contributions to successful drug development programs.  Mr. Whitehead is a seasoned financial executive who will continue to serve as Amorfix Chief Financial officer and who brings many years of experience in financial management to the Board".  

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information: Dr. Robert Gundel, President and Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6957, Fax: (416) 847-6899, bob.gundel@amorfix.com; Warren Whitehead, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 644-7358, Fax: (416) 847-6899, warren.whitehead@amorfix.com